AB
ABEO.PA
—
Euronext Paris
Diversified Pharmaceuticals
Abeo.Pa
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
3,78 %
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
ABEO.PA operates in the Recreational Products industry, producing and selling consumer goods for leisure and recreational activities.
Business. Abeona Therapeutics Inc (ABEO.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. The company operates within the Healthcare sector, specifically focusing on the development and potential sale of pharmaceutical products. No specific operating segments or geographic revenue breakdowns are provided in the available data.
Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target17,50
Analyst recommendations
2 analysts · consensus BuyBuy2
Hold0
Sell0
12-month price target
17,50
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ABEO.PA. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Abeona Therapeutics Inc (ABEO.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. The company operates within the Healthcare sector, specifically focusing on the development and potential sale of pharmaceutical products. No specific operating segments or geographic revenue breakdowns are provided in the available data.
Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
AI synthesis
GENERATED— missing data
Key takeaways
- ABEO.PA has no dilution risk from stock options or convertible securities.
- Analysts have assigned a strong-buy recommendation to ABEO.PA.
- Liquidity risk could not be assessed due to missing balance-sheet data.
- No segment or geographic exposure data is available for ABEO.PA.
- Growth trajectory and profitability metrics are not quantifiable with the current data.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
€9,00
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Supply chain
Vendors → ABEO ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-04Peer comparison
Peer comparison8 peers · vs ABEO · multiples and returns
MC
MCK—
Mckesson Corp
$827,14
102,6B USDP/E
21,2x
+16,5 vs self
Div yield
0,4 %
— vs self
ROE
-219,2 %
-263,9 vs self
CO
COR—
Cencora Inc
$308,37
60,2B USDP/E
36,4x
+31,7 vs self
Div yield
0,8 %
— vs self
ROE
45,7 %
+1,0 vs self
CA
CAH—
Cardinal Health Inc
$235,60
57,0B USDP/E
36,7x
+32,0 vs self
Div yield
0,9 %
— vs self
ROE
-55,9 %
-100,6 vs self
DB
DB—
DB.V
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
RE
REGN—
REGENERON PHARMACEUTICALS, INC.
$757,99
81,0B USDP/E
15,5x
+10,8 vs self
Div yield
—
— vs self
ROE
14,2 %
-30,5 vs self
BI
BIIB—
BIOGEN INC.
$201,74
29,6B USDP/E
21,3x
+16,6 vs self
Div yield
—
— vs self
ROE
7,5 %
-37,2 vs self
ZT
ZTS—
Zoetis Inc
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
GR
GRFS—
Grifols SA
$7,86
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
1,47
Predicted surprise
+0,00
Beat probability
45 %
Analysts
2
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-10 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,47 |
| Revenue | —no estimate | —no estimate | 282,0M EUR |
| Operating income | —no estimate | —no estimate | 19,5M EUR |
Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution2 analysts
Strong buy2
Buy0
Hold0
Sell0
Strong sell0
12-month price target€17,50 · Median €17,50
Low €15,00High €20,00
Operating income · consensus19,5M EUR
EPS surprise
−38,8 %
reported vs consensus · miss
Revenue surprise
−11,8 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low€15,00
Mean€17,50
Median€17,50
High€20,00
Spot€9,00
+94.4 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Source documents
- ABEO.PA Market data — financials · 2026-05-27
- Abeo SA Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Olivier EstevesChairman of the Board, Chief Executive Officer
Insider activity
Net selling0 buys · 20 sellsnet -$1,5M13 insiders · last 365d
- Chief Commercial Officer · Common StockOther 222 @ $5,67$1K · 2026-06-16
- Director · Common StockSold 18 160 @ $5,71$104K · 2026-06-15
- Chief Financial Officer · Common StockSold 13 421 @ $5,30$71K · 2026-06-09
- SVP, Chief Legal Officer · Common StockSold 6 305 @ $5,30$33K · 2026-06-09
- Director, Chief Executive Officer · Common StockSold 31 916 @ $5,30$169K · 2026-06-09
- Chief Commercial Officer · Common StockSold 5 450 @ $5,30$29K · 2026-06-09
- Chief Financial Officer · Common StockSold 25 646 @ $5,39$138K · 2026-06-09
- Chief Commercial Officer · Common StockSold 4 170 @ $5,43$23K · 2026-06-08
- Chief Financial Officer · Common StockSold 10 271 @ $5,43$56K · 2026-06-08
- SVP, Chief Legal Officer · Common StockSold 4 826 @ $5,43$26K · 2026-06-08
- Director, Chief Executive Officer · Common StockSold 24 428 @ $5,43$133K · 2026-06-08
- Director · Common StockOther 500 · 2026-05-26
- Director · Common StockSold 6 500 @ $5,46$35K · 2026-05-22
- Director · Common StockSold 26 143 @ $5,53$145K · 2026-05-15
- Chief Commercial Officer · Common StockSold 5 548 @ $5,96$33K · 2026-05-11
- Director · Common StockOther 32 751 · 2026-04-01
- Director, Chief Executive Officer · Common StockSold 29 985 @ $4,38$131K · 2026-03-31
- Chief Financial Officer · Common StockSold 785 @ $4,76$4K · 2026-03-16
- Director · Common StockSold 2 000 @ $5,09$10K · 2026-02-02
- Director · Common StockSold 14 814 @ $5,09$75K · 2026-02-02
- Director · Common StockSold 20 070 @ $5,09$102K · 2026-02-02
- Director · Common StockSold 16 284 @ $5,09$83K · 2026-02-02
- Director · Common StockSold 18 065 @ $5,09$92K · 2026-02-02
- Director · Common StockOther 37 313 · 2026-01-26
- Director · Common StockOther 37 313 · 2026-01-26
Short positioning
13.2Mshares short-3.3% vs prior
8.28days to cover
53.9%short of daily vol
23fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ABEO.PACanonical
Euronext Paris · EUR
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskUnknown
Relationship graph
This companySectorCustomers
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -7.0%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2023-12-31): 66.3%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -36.3%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 5.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 235.8%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -39.3%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 226.0%Derived (calculated)
- Return on equity (FY 2025-12-31): -44.7%Derived (calculated)
- Return on assets (FY 2025-12-31): -32.4%Derived (calculated)
- Current ratio (FY 2025-12-31): 6.93xDerived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -211.7%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.38xDerived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 261.6%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 165.2%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 101.6%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -22.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 186.5%Derived (calculated)
- Net margin (FY 2025-12-31): -1,223.1%Derived (calculated)
- Total assets (annual): USD 219.57MSEC XBRL filing
- Long-term debt (annual): USD 20.04MSEC XBRL filing
- R&D expense (annual): USD 26.81MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 1SEC XBRL filing
- Operating cash flow (annual): USD -76.33MSEC XBRL filing
- Revenue (annual): USD 5.82MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-16 00:00 UTCINSIDER11 insider transactions — 2026-06 · net sell $783k
2026-06-16INSIDERVasanthavada Madhav transacted 222 sh — Chief Commercial Officer ~$1k
2026-06-15INSIDERSilverstein Christine Berni sold 18.2k sh — Director ~$104k
2026-06-09INSIDERO'Malley Brendan M. sold 6.3k sh — SVP, Chief Legal Officer ~$33k
2026-06-09INSIDERVazzano Joseph Walter sold 13.4k sh — Chief Financial Officer ~$71k
2026-06-09INSIDERVazzano Joseph Walter sold 25.6k sh — Chief Financial Officer ~$138k
2026-06-09INSIDERVasanthavada Madhav sold 5.5k sh — Chief Commercial Officer ~$29k
2026-06-09INSIDERSeshadri Vishwas sold 31.9k sh — Director, Chief Executive Officer ~$169k
2026-06-08INSIDERSeshadri Vishwas sold 24.4k sh — Director, Chief Executive Officer ~$133k
2026-06-08INSIDERO'Malley Brendan M. sold 4.8k sh — SVP, Chief Legal Officer ~$26k
2026-06-08INSIDERVazzano Joseph Walter sold 10.3k sh — Chief Financial Officer ~$56k
2026-06-08INSIDERVasanthavada Madhav sold 4.2k sh — Chief Commercial Officer ~$23k
2026-05-26 00:00 UTCINSIDER4 insider transactions — 2026-05 · net sell $213k
2026-05-26INSIDERAlvino Mark transacted 500 sh — Director
2026-05-22INSIDERAlvino Mark sold 6.5k sh — Director ~$35k
2026-05-15INSIDERCrombez Eric sold 26.1k sh — Director ~$145k
2026-05-11INSIDERVasanthavada Madhav sold 5.5k sh — Chief Commercial Officer ~$33k
2026-04-01 00:00 UTCINSIDER1 insider transaction — 2026-04
2026-04-01INSIDERGoldan Keith A. transacted 32.8k sh — Director
2026-03-31 00:00 UTCINSIDER2 insider transactions — 2026-03 · net sell $135k
2026-03-31INSIDERSeshadri Vishwas sold 30.0k sh — Director, Chief Executive Officer ~$131k
Showing the 40 most recent of 53 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage